NeuBase Therapeutics, Inc. announced a private placement of 1,366,829 common shares at an issue price of $2.57 per share for gross proceeds of $3,512,750.53 on June 28, 2023. The company also issued unregistered Series A warrants to purchase up to an aggregate of 1,945,526 shares of common stock and unregistered short-term Series B warrants to purchase up to an aggregate of 1,945,526 shares of common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4396 USD | -0.54% | +2.23% | -40.60% |
Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
Mar. 26 | US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings | MT |
1st Jan change | Capi. | |
---|---|---|
-40.60% | 1.65M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NBSE Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. announced that it expects to receive $3.512751 million in funding